Cyclosporine 0.1% (Ikervis®) treatment in steroid-dependent dupilumab-associated conjunctivitis

Arch Soc Esp Oftalmol (Engl Ed). 2019 Aug;94(8):396-399. doi: 10.1016/j.oftal.2019.04.013. Epub 2019 Jun 6.
[Article in English, Spanish]

Abstract

Dupilumab is a drug that has recently been approved by the Food and Drug Administration (FDA) and European Medical Agency (EMA) for the treatment of moderate-to-severe atopic dermatitis in adults. An increase in frequency of conjunctivitis related to dupilumab treatment has been reported in recent publications and clinical trials. We report two steroid-dependent cases satisfactorily treated with cyclosporine 0.1% (Ikervis®). To our knowledge there are no reported cases of dupilumab-associated conjunctivitis treated with cyclosporine 0.1% (Ikervis®).

Keywords: Atopic dermatitis; Ciclosporina; Conjunctivitis; Conjuntivitis; Cyclosporine; Dermatitis atópica; Dupilumab.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Conjunctivitis / chemically induced*
  • Conjunctivitis / diagnostic imaging
  • Conjunctivitis / drug therapy*
  • Cyclosporine / therapeutic use*
  • Dermatitis, Atopic / drug therapy*
  • Female
  • Fluorometholone / therapeutic use
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Interleukin-4 Receptor alpha Subunit
  • Male
  • Middle Aged
  • Recurrence

Substances

  • Adrenal Cortex Hormones
  • Antibodies, Monoclonal, Humanized
  • Glucocorticoids
  • Immunosuppressive Agents
  • Interleukin-4 Receptor alpha Subunit
  • dupilumab
  • Cyclosporine
  • Fluorometholone